U.S. Markets closed

Notable Insider Buys This Past Week: DXC Technology, HealthEquity

Nelson Hem
  • Insider buying can be an encouraging signal for potential investors.
  • A pair of CEOs stepped up while insider buying was slow overall.
  • Some insiders took advantage of a public offering of shares as well.

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly with markets near all-time highs.

Below is a look at a couple of notable insider purchases reported in the past week, but also note that an insider bought some FedEx Corporation (NYSE: FDX) shares while others were exercising options and selling.

HealthEquity

Healthequity Inc (NASDAQ: HQY) CEO Jon Kessler, founder Stephen Neeleman and two other directors took advantage of a public offering of shares. At $61.00 apiece, the 40,000 shares acquired altogether totaled $2.44 million. Note that two other insiders exercised options on almost 16,000 shares of this health savings accounts custodian as well.

HealthEquity recently announced the acquisition of Wageworks, a health care benefits administrator. HealthEquity's shares ended the third week of July more than 11% higher, while the S&P 500 retreated marginally. The stock closed most recently at $79.18, well above the offering purchase price. Note that shares have traded as high as $101.58 in the past 52 weeks, but the analysts' consensus price target is $89.20.

See Also: 7 Pros And Cons Of Online Banking

DXC Technology

The CEO of DXC Technology Co (NYSE: DXC), John Lawrie, stepped up and purchased more than 4,100 shares of this IT services provider last week. At prices ranging from $55.62 to $56.69 per share, that cost him more than $234,000. Note that these purchases were made pursuant to a 10b5-1 Plan and brought his stake up to almost 898,000 shares.

The company recently announced the expansion of its strategic partnership with Microsoft. The stock ended the past week at $55.93 per share, just a little higher than this chief executive's purchase range. While the consensus analyst target was last seen at $73.00, the stock has traded as high as $96.75 in the past 12 months.

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.